In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Skips Critical Measures In Step-By-Step 'Cures'

This article was originally published in Scrip

Executive Summary

While many stakeholders in the biomedical community were happy just to see the Senate Health, Education, Labor and Pensions (HELP) Committee finally unveil a plan for moving forward with legislation aimed at making changes at the FDA and the National Institutes of Health (NIH) intended to accelerate medical innovation, there also was disappointment that the step-by-step strategy proposed by Sen. Lamar Alexander (R-TN), the panel's chairman, ignores several measures, like one focused on antibiotics development, that were included in a mega-bill adopted by the House last July – the 21st Century Cures Act.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts